Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
14.49
0.00 (0.00%)
Apr 24, 2026, 4:00 PM EDT - Market closed
Amicus Therapeutics Employees
Amicus Therapeutics had 511 employees as of December 31, 2025. The number of employees increased by 12 or 2.40% compared to the previous year.
Employees
511
Change (1Y)
12
Growth (1Y)
2.40%
Revenue / Employee
$1,241,115
Profits / Employee
-$53,053
Market Cap
4.55B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Apellis Pharmaceuticals | 739 |
| Corcept Therapeutics | 730 |
| Crinetics Pharmaceuticals | 594 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Scholar Rock Holding | 289 |
FOLD News
- 4 weeks ago - Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications - Business Wire
- 2 months ago - Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 3 months ago - Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 - GlobeNewsWire
- 3 months ago - Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
- 4 months ago - Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD - Business Wire
- 4 months ago - BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. - Barrons
- 4 months ago - BioMarin to Buy Amicus Therapeutics for $4.8 Billion - WSJ
- 4 months ago - BioMarin to acquire Amicus Therapeutics for $4.8 Billion - Reuters